Open
Actively Recruiting
FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma
About
Brief Summary
This pilot clinical trial studies fluordeoxyglucose (fludeoxyglucose) F-18 (FDG) positron emission tomography (PET)/computed tomography (CT) in monitoring very early therapy response in patients with glioblastoma. Diagnostic procedures, such as FDG PET/CT, may help measure a patient's response to earlier treatment. Chemotherapy can induce very rapid changes to the tumor's glucose consumption which can be measured with imaging. FDG PET/CT shortly after the start of therapy may help identify very early therapy response in patients with glioblastoma.
Primary Purpose
Study Type
Phase
Eligibility
Gender
Healthy Volunteers
Minimum Age
Maximum Age
Inclusion Criteria:
- Patients with histologically proven high grade glioma
- Intention to start therapy
Exclusion Criteria:
- Severe psychiatric illness
- Inability to give written consent
- Breast feeding / pregnancy
Join this Trial
Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
15-000409
Category
Brain Cancer
Principal Investigator
Benjamin Ellingson
Contact
Location
- UCLA Westwood